Fresenius Medical Care AG (NYSE:FMS) hit a new 52-week high during trading on Tuesday . The stock traded as high as $47.52 and last traded at $47.36, with a volume of 214,306 shares trading hands. The stock had previously closed at $45.95.

A number of research firms have issued reports on FMS. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday, July 8th. DZ Bank AG reiterated a “neutral” rating on shares of Fresenius Medical Care AG in a research report on Thursday, August 4th. Royal Bank Of Canada reiterated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Zacks Investment Research upgraded shares of Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $42.50.

The company has a 50-day moving average of $44.23 and a 200 day moving average of $43.29. The firm has a market cap of $28.62 billion and a P/E ratio of 25.95.

Fresenius Medical Care AG (NYSE:FMS) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported $0.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.04. The firm had revenue of $4.42 billion for the quarter, compared to analyst estimates of $4.54 billion. Equities research analysts forecast that Fresenius Medical Care AG will post $2.01 earnings per share for the current year.

A number of hedge funds and institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its position in shares of Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares in the last quarter. WBI Investments Inc. purchased a new position in shares of Fresenius Medical Care AG during the fourth quarter worth about $2,249,000. Bank of Montreal Can boosted its position in shares of Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares in the last quarter. Morgan Stanley boosted its position in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares in the last quarter. Finally, Comerica Bank boosted its position in shares of Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.